title: D-tagatose, a stereoisomer of D-fructose, increases blood uric acid concentration.
abstract: D-Fructose has been found to increase uric acid production by accelerating the degradation of purine nucleotides, probably due to hepatocellular depletion of inorganic phosphate (Pi) by an accumulation of ketohexose-1-phosphate. The hyperuricemic effect of D-tagatose, a stereoisomer of D-fructose, may be greater than that of D-fructose, as the subsequent degradation of D-tagatose-1-phosphate is slower than the degradation of D-fructose-1-phosphate. We tested the effect of 30 g oral D-tagatose versus D-fructose on plasma uric acid and other metabolic parameters in 8 male subjects by a double-blind crossover design. Both the peak concentration and 4-hour area under the curve (AUC) of serum uric acid were significantly higher after D-tagatose compared with either 30 g D-fructose or plain water. The decline in serum Pi concentration was greater at 50 minutes after D-tagatose versus D-fructose. The thermogenic and lactacidemic responses to D-tagatose were blunted compared with D-fructose. D-Tagatose attenuated the glycemic and insulinemic responses to a meal that was consumed 255 minutes after its administration. Moreover, both fructose and D-tagatose increased plasma concentrations of cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1). The metabolic effects of D-tagatose occurred despite its putative poor absorption.
authors.affiliation: Research Department of Human Nutrition, The Royal Veterinary and Agricultural University, Frederiksberg, Denmark.
authors.forename: B
authors.initials: B
authors.lastname: Buemann
authors.forename: S
authors.initials: S
authors.lastname: Toubro
authors.forename: J J
authors.initials: JJ
authors.lastname: Holst
authors.forename: J F
authors.initials: JF
authors.lastname: Rehfeld
authors.forename: B M
authors.initials: BM
authors.lastname: Bibby
authors.forename: A
authors.initials: A
authors.lastname: Astrup
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001066:Appetite / Q000187:drug effects; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D002153:Calorimetry, Indirect; D002766:Cholecystokinin / Q000097:blood; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004734:Energy Metabolism / Q000187:drug effects; D004837:Epinephrine / Q000097:blood; D018565:Food-Drug Interactions; D005632:Fructose / Q000494:pharmacology; D005749:Gastric Inhibitory Polypeptide / Q000097:blood; D005934:Glucagon / Q000097:blood; D052216:Glucagon-Like Peptide 1; D006601:Hexoses / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D008297:Male; D009638:Norepinephrine / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D011498:Protein Precursors / Q000097:blood; D013237:Stereoisomerism; D013549:Sweetening Agents / Q000493:pharmacokinetics / Q000494:pharmacology; D014527:Uric Acid / Q000097:blood* / Q000652:urine
chemical_list: D001786:Blood Glucose; D006601:Hexoses; D010446:Peptide Fragments; D011498:Protein Precursors; D013549:Sweetening Agents; D014527:Uric Acid; D005632:Fructose; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D002766:Cholecystokinin; C030192:tagatose; D009638:Norepinephrine; D004837:Epinephrine